

## **India Oral Anti-Diabetic Drug - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029**

Market Report | 2024-02-17 | 70 pages | Mordor Intelligence

### **AVAILABLE LICENSES:**

- Single User License \$4750.00
- Team License (1-7 Users) \$5250.00
- Site License \$6500.00
- Corporate License \$8750.00

### **Report description:**

The India Oral Anti-Diabetic Drug Market size is estimated at USD 1.7 billion in 2024, and is expected to reach USD 2.01 billion by 2029, growing at a CAGR of 3.5% during the forecast period (2024-2029).

Infections with COVID-19, which started about two years ago, have increased by almost 25% in India. India is regarded as the diabetes capital because there are over 80 million diabetics there. Hypoxia, weakness, weight loss, hair loss, myocarditis, and thyroid issues are just a few of the recurring and new health issues that have been related to COVID. This viral infection causes a variety of inflammatory reactions. Yet, one of the most common adverse effects of infectious illness is reported to be diabetes. Dr. Anoop Misra, a renowned endocrinologist from Delhi, claims that thyroid problems and new-onset diabetes are common in COVID-19 patients globally. He proposed two possible explanations: "some unfurling of autoimmunity" (when the body's immune system makes a mistake and attacks its tissues and organs) and/or "severe repercussions of cytokine surge," a powerful immunological reaction observed in some Covid patients.

One in six people with diabetes worldwide, according to an article in "THE HINDU," is Indian. With an estimated 80 million diabetics, the country ranks second among the top 10 countries for those with the disease. In India, more than 50% of the population is at risk of developing diabetes at some point in their lives, making it a serious public health issue. Rural parts of India are also experiencing an increase in the incidence of type 2 diabetes. After lifestyle changes, oral anti-diabetic medications play a significant role in the management of diabetes. Dipeptidyl peptidase 4 (DPP4) inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors are two novel medications that can be used alone or in combination with existing glucose-lowering medications, such as insulin, when diet and exercise alone are insufficient, and metformin is not tolerated. These drugs have different therapeutic, pharmacokinetic, and safety properties than the more established drugs. Recently approved drugs like bromocriptine and hydroxychloroquine (hcq) have positive effects on blood sugar and HbA1C levels. Sulfonylureas (SU) were the only licensed

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

insulin rivals until metformin was approved, and they were widely employed to treat T2DM. While there are now just three SU medications that can be prescribed.

## India Oral Anti-Diabetic Drug Market Trends

### Sodium-glucose Cotransport-2 (SGLT-2) inhibitor Segment Occupied the Highest Market Share in India Oral Anti-Diabetic Drugs Market in 2022

In terms of revenue, the Sodium-glucose cotransport -2 (SGLT-2) inhibitor segment is anticipated to lead the India Oral Anti-Diabetic Drugs Market and post a CAGR of over 11% during the course of the forecast year.

Type 2 diabetes is treated using a group of drugs called Sodium-glucose cotransport -2 (SGLT-2) inhibitors, some of which have also been approved to treat obesity. One of its benefits is that they are less likely to cause hypoglycemia than more traditional insulin secretagogues like sulfonylureas or meglitinides. In addition to significantly lowering blood sugar, SGLT2As have significant effects on the makeup of gut bacteria, lung protection, and inflammation. As a result, SGLT2s have proven to be effective anti-diabetic (glucose-lowering) drugs during the COVID-19 pandemic times as well as potential candidates for treating COVID-19 infection-infected individuals, whether or not they have type 2 diabetes. The National Health Program is divided into basic aid tiers, each of which can be specifically defined in a given place. The National Health Program is structured according to LEAs. The LEAs specify all medical assistance programs offered by the INHS to citizens, with or without a patient's income-based partial contribution. Diabetes, a serious health disease, is one of the main issues Italian healthcare institutions are currently confronting. The progression of the disease, its rising prevalence, and the need for more treatment choices for diabetes patients have sparked the creation of novel drugs. The launch of various new products, developing international research collaborations for technical improvement, and increasing public awareness of diabetes are some of the potential opportunities for enterprises in the Indian diabetes pharmaceutical market.

Increasing Diabetes Population in India is driving the market.

Diabetes, a long-term condition, is a silent killer. Several medical professionals cautioned that patients with comorbid conditions are particularly vulnerable to the virus during the initial COVID-19 wave last year. Diabetes mellitus, generally known as diabetes, is a metabolic condition characterized by high blood sugar levels. A complete lack of insulin results in type 1 diabetes, also known as insulin-dependent diabetes mellitus. With type 2 diabetes mellitus, the body either produces insufficient amounts of insulin or is unable to use the insulin that is produced. According to some, type 2 diabetes is a lifestyle condition. Sugary treats are a hallmark of Indian culture and are consumed during many religious festivals and old customs. It is therefore anticipated to drive the category expansion during the forecast period because of the aforementioned factors. Unfortunately, with more patients being added each year, India has become the world's diabetes capital. This is a key source of concern for the Center as well as adding to the growing cost of healthcare on the Indian economy. The government is aware of this and appears to be acting to combat it by lowering the price of a few recently released diabetes medications. Pharma companies are also recognizing a new development opportunity by developing novel medications and therapeutic fusions.

## India Oral Anti-Diabetic Drug Industry Overview

India's oral anti-diabetes drug market is consolidated, with a few major manufacturers like Eli Lilly, AstraZeneca, Sanofi, and Janssen Pharmaceuticals having a global market presence. In contrast, the remaining manufacturers are confined to the other local or regional markets. Companies are focusing on innovations in diabetes drugs.

Additional Benefits:

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

## **Table of Contents:**

### 1 INTRODUCTION

- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study

### 2 RESEARCH METHODOLOGY

### 3 EXECUTIVE SUMMARY

### 4 MARKET DYNAMICS

- 4.1 Market Overview
- 4.2 Market Drivers
- 4.3 Market Restraints
- 4.4 Porter's Five Forces Analysis
  - 4.4.1 Bargaining Power of Suppliers
  - 4.4.2 Bargaining Power of Consumers
  - 4.4.3 Threat of New Entrants
  - 4.4.4 Threat of Substitute Products and Services
  - 4.4.5 Intensity of Competitive Rivalry

### 5 MARKET SEGMENTATION

- 5.1 Oral Anti-diabetic Drugs (Value and Volume, 2017 - 2028)
  - 5.1.1 Biguanides
    - 5.1.1.1 Metformin
  - 5.1.2 Alpha-Glucosidase Inhibitors
    - 5.1.2.1 Alpha-Glucosidase Inhibitors
  - 5.1.3 Dopamine D2 receptor agonist
    - 5.1.3.1 Bromocriptin
  - 5.1.4 SGLT-2 inhibitors 
    - 5.1.4.1 Invokana (Canagliflozin)
    - 5.1.4.2 Jardiance (Empagliflozin)
    - 5.1.4.3 Farxiga/Forxiga (Dapagliflozin)
    - 5.1.4.4 Suglat (Ipragliflozin)
  - 5.1.5 DPP-4 inhibitors
    - 5.1.5.1 Onglyza (Saxagliptin)
    - 5.1.5.2 Tradjenta (Linagliptin)
    - 5.1.5.3 Vipidia/Nesina (Alogliptin)
    - 5.1.5.4 Galvus (Vildagliptin)
  - 5.1.6 Sulfonylureas
    - 5.1.6.1 Sulfonylureas
  - 5.1.7 Meglitinides
    - 5.1.7.1 Meglitinides

### 6 MARKET INDICATORS

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

6.1 Type-1 Diabetic Population (2017 - 2028)

6.2 Type-2 Diabetic Population (2017 - 2028)

## 7 COMPETITIVE LANDSCAPE

### 7.1 COMPANY PROFILES

7.1.1 Takeda

7.1.2 Novo Nordisk

7.1.3 Pfizer

7.1.4 Eli Lilly

7.1.5 Janssen Pharmaceuticals

7.1.6 Astellas

7.1.7 Boehringer Ingelheim

7.1.8 Merck And Co.

7.1.9 AstraZeneca

7.1.10 Bristol Myers Squibb

7.1.11 Novartis

7.1.12 Sanofi

## 8 MARKET OPPORTUNITIES AND FUTURE TRENDS

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**India Oral Anti-Diabetic Drug - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029**

Market Report | 2024-02-17 | 70 pages | Mordor Intelligence

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$4750.00
	Team License (1-7 Users)	\$5250.00
	Site License	\$6500.00
	Corporate License	\$8750.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-01"/>
		Signature	

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

